Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal
By Don Nico Forbes
Shares in Liquidia rose after the U.S. Supreme Court rejected an appeal by United Therapeutics in the fellow biotech company's patent dispute.
Shares were recently up 12% at $11.20.
The court rejected United's appeal over a decision to invalidate its patent claims concerning Liquidia's drug Yutrepia, with the decision now final and not subject to further appeal, Liquidia said.
United claims the drug infringes on its patent covering the inhaled administration of the drug treprostinil. Yutrepia is an inhaled version of treprostinil. Liquidia sells treprostinil in pills, powder and injections.
On May 31, a U.S. district court had denied United's request for a preliminary injunction.
The U.S. Food and Drug Administration gave tentative approval for Yutrepia to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in August, the company said. Final approval may occur after the expiration of three-year regulatory exclusivity for Tyvaso DPI on May 23, 2025, it added.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
October 07, 2024 11:14 ET (15:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Is 16% a Good Return?
-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
New 4-Star Stocks
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts